You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFosinopril
Accession NumberDB00492  (APRD00526)
TypeSmall Molecule
GroupsApproved
Description

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
(2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
(2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
Fosinopril
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-fosinopriltablet20 mgoralAvanstra Inc2011-11-282014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ava-fosinopriltablet10 mgoralAvanstra Inc2011-11-282014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Fosinopril Tabletstablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Fosinopril Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Fosinopril-10tablet10 mgoralPro Doc Limitee2008-10-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Fosinopril-20tablet20 mgoralPro Doc Limitee2008-10-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-fosinopriltablet20 mgoralJamp Pharma Corporation2010-05-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jamp-fosinopriltablet10 mgoralJamp Pharma Corporation2010-05-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Lin-fosinopriltablet20 mgoralLinson Pharma Co.2004-03-302008-07-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Lin-fosinopriltablet10 mgoralLinson Pharma Co.2004-03-302008-07-16Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Monopril Tab 10mgtablet10 mgoralBristol Myers Squibb Canada1992-12-312013-06-17Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Monopril Tab 20mgtablet20 mgoralBristol Myers Squibb Canada1992-12-312013-06-17Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-fosinopriltablet20 mgoralMylan Pharmaceuticals Ulc2004-12-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-fosinopriltablet10 mgoralMylan Pharmaceuticals Ulc2004-12-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-fosinopriltablet20 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-fosinopriltablet10 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-fosinopriltablet20 mgoralPharmel IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-fosinopriltablet10 mgoralPharmel IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-fosinopriltablet20 mgoralPharmascience Inc2005-02-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-fosinopriltablet10 mgoralPharmascience Inc2005-02-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ran-fosinopriltablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-08-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ran-fosinopriltablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-08-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio Fosinopriltablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio Fosinopriltablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Riva-fosinopriltablet20 mgoralLaboratoire Riva Inc2005-06-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Riva-fosinopriltablet10 mgoralLaboratoire Riva Inc2005-06-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-fosinopriltablet10 mgoralTeva Canada Limited2003-12-05Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-fosinopriltablet20 mgoralTeva Canada Limited2003-12-05Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fosinopriltablet20 mgoralApotex Inc2005-04-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-fosinopriltablet10 mgoralApotex Inc2005-04-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Fosinopril Natablet40 mg/1oralApotex Corp.2005-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Natablet20 mg/1oralApotex Corp.2005-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Natablet10 mg/1oralApotex Corp.2005-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralREMEDYREPACK INC.2016-01-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralPhysicians Total Care, Inc.2004-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc2005-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralSt Marys Medical Park Pharmacy2014-05-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralPhysicians Total Care, Inc.2004-04-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralAphena Pharma Solutions Tennessee, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralUnit Dose Services2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralUnit Dose Services2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc2005-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet10 mg/1oralbryant ranch prepack2007-09-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet40 mg/1oralPhysicians Total Care, Inc.2004-11-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Fosinopril Sodiumtablet20 mg/1oralDispensing Solutions, Inc.2004-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AcecorSPA (Czech Republic)
MonoprilBristol-Myers Squibb
StarilBMS (United Kingdom)
Brand mixtures
NameLabellerIngredients
Fosinopril Sodium and HydrochlorothiazideEon Labs, Inc.
Salts
Name/CASStructureProperties
Fosinopril Sodium
88889-14-9
Thumb
  • InChI Key: TVTJZMHAIQQZTL-HREVRLCXSA-M
  • Monoisotopic Mass: 585.283133986
  • Average Mass: 585.6443
DBSALT000193
CategoriesNot Available
CAS number98048-97-6
WeightAverage: 563.6625
Monoisotopic: 563.301189343
Chemical FormulaC30H46NO7P
InChI KeyInChIKey=BIDNLKIUORFRQP-FKDWWROVSA-N
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
IUPAC Name
(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid
SMILES
CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Phosphinic acid ester
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organophosphorus compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
PharmacodynamicsFollowing oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
AbsorptionAverage absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.
Volume of distributionNot Available
Protein bindingFosinoprilat is ≥95% protein bound
Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

SubstrateEnzymesProduct
Fosinopril
Not Available
FosinoprilatDetails
Route of eliminationAfter oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.
Half life12 hours
Clearance
  • 26 – 39 mL/min [healthy]
ToxicityHuman overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9532
Blood Brain Barrier-0.667
Caco-2 permeable-0.6561
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.6774
Renal organic cation transporterNon-inhibitor0.812
CYP450 2C9 substrateNon-substrate0.7028
CYP450 2D6 substrateNon-substrate0.8128
CYP450 3A4 substrateSubstrate0.6729
CYP450 1A2 substrateNon-inhibitor0.8913
CYP450 2C9 inhibitorNon-inhibitor0.7438
CYP450 2D6 inhibitorNon-inhibitor0.9004
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorNon-inhibitor0.7303
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6376
Ames testNon AMES toxic0.7141
CarcinogenicityNon-carcinogens0.8025
BiodegradationNot ready biodegradable0.8102
Rat acute toxicity2.8211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9534
hERG inhibition (predictor II)Non-inhibitor0.5918
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc etobicoke site
  • Invagen pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral
Tabletoral10 mg
Tabletoral20 mg
Prices
Unit descriptionCostUnit
Monopril HCT 10-12.5 mg tablet1.71USD tablet
Monopril 10 mg tablet1.68USD tablet
Monopril 40 mg tablet1.67USD tablet
Monopril 20 mg tablet1.62USD tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet1.61USD tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet1.61USD tablet
Fosinopril sodium 20 mg tablet1.25USD tablet
Fosinopril sodium 40 mg tablet1.25USD tablet
Fosinopril sodium 10 mg tablet1.21USD tablet
Monopril 20 mg Tablet1.1USD tablet
Monopril 10 mg Tablet0.91USD tablet
Apo-Fosinopril 20 mg Tablet0.61USD tablet
Fosinopril 20 mg Tablet0.61USD tablet
Jamp-Fosinopril 20 mg Tablet0.61USD tablet
Mylan-Fosinopril 20 mg Tablet0.61USD tablet
Novo-Fosinopril 20 mg Tablet0.61USD tablet
Ran-Fosinopril 20 mg Tablet0.61USD tablet
Apo-Fosinopril 10 mg Tablet0.51USD tablet
Fosinopril 10 mg Tablet0.51USD tablet
Jamp-Fosinopril 10 mg Tablet0.51USD tablet
Mylan-Fosinopril 10 mg Tablet0.51USD tablet
Novo-Fosinopril 10 mg Tablet0.51USD tablet
Ran-Fosinopril 10 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States50063441993-01-102010-01-10
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point149-153 °CNot Available
water solubilityInsolubleNot Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00101 mg/mLALOGPS
logP4.71ALOGPS
logP5.49ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.87ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.21 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity149.12 m3·mol-1ChemAxon
Polarizability61.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, “Preparation of crystalline polymorphs of fosinopril sodium.” U.S. Patent US20050010054, issued January 13, 2005.

US20050010054
General References
  1. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. Pubmed
  2. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. Pubmed
External Links
ATC CodesC09AA09
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (206 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Fosinopril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Fosinopril.
AliskirenAliskiren may increase the hyperkalemic activities of Fosinopril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.
Aluminum hydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.
AmifostineFosinopril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Fosinopril.
ArdeparinArdeparin may increase the hyperkalemic activities of Fosinopril.
AzathioprineFosinopril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Fosinopril.
ButabarbitalButabarbital may increase the hypotensive activities of Fosinopril.
ButethalButethal may increase the hypotensive activities of Fosinopril.
Calcium carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Calcium carbonate.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Fosinopril.
CiprofloxacinFosinopril may increase the arrhythmogenic activities of Ciprofloxacin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.
DiazoxideDiazoxide may increase the hypotensive activities of Fosinopril.
DrospirenoneFosinopril may increase the hyperkalemic activities of Drospirenone.
DuloxetineFosinopril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Fosinopril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.
HeparinHeparin may increase the hyperkalemic activities of Fosinopril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Fosinopril.
HexobarbitalHexobarbital may increase the hypotensive activities of Fosinopril.
IcatibantIcatibant may decrease the antihypertensive activities of Fosinopril.
InfliximabThe risk or severity of adverse effects can be increased when Fosinopril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.
LanthanumThe serum concentration of Fosinopril can be decreased when it is combined with Lanthanum.
LevodopaFosinopril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Fosinopril.
Magnesium hydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
MethohexitalMethohexital may increase the hypotensive activities of Fosinopril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fosinopril.
MolsidomineMolsidomine may increase the hypotensive activities of Fosinopril.
MoxonidineMoxonidine may increase the hypotensive activities of Fosinopril.
NicorandilNicorandil may increase the hypotensive activities of Fosinopril.
ObinutuzumabFosinopril may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Fosinopril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fosinopril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Fosinopril.
PregabalinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Fosinopril.
QuinineQuinine may increase the hypotensive activities of Fosinopril.
RisperidoneFosinopril may increase the hypotensive activities of Risperidone.
RituximabFosinopril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sacubitril.
Salicylate-sodiumSalicylate-sodium may decrease the antihypertensive activities of Fosinopril.
SecobarbitalSecobarbital may increase the hypotensive activities of Fosinopril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sodium aurothiomalate.
Sodium bicarbonateThe serum concentration of Fosinopril can be decreased when it is combined with Sodium bicarbonate.
TadalafilTadalafil may increase the antihypertensive activities of Fosinopril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Fosinopril.
TizanidineTizanidine may increase the hypotensive activities of Fosinopril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Fosinopril.
TorasemideTorasemide may increase the hypotensive activities of Fosinopril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Fosinopril.
TreprostinilTreprostinil may increase the hypotensive activities of Fosinopril.
TriamtereneTriamterene may increase the hyperkalemic activities of Fosinopril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Fosinopril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fosinopril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.
VardenafilVardenafil may increase the antihypertensive activities of Fosinopril.
YohimbineYohimbine may decrease the antihypertensive activities of Fosinopril.
Food Interactions
  • Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
  • Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of fosinopril.
  • Take without regard to meals.

Targets

1. Angiotensin-converting enzyme

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Angiotensin-converting enzyme P12821 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. Pubmed
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. Pubmed
  4. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. Pubmed

Transporters

1. Solute carrier family 15 member 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 15 member 1 P46059 Details

References:

  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19. Pubmed

2. Solute carrier family 15 member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 15 member 2 Q16348 Details

References:

  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. Epub 2008 Aug 19. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:10